Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim about methotrexate/Rasuvo causing embryo-fetal toxicity including fetal death and that severe toxic reactions can be fatal is directly supported by the boxed warning and related warning/pregnancy sections in the supplied label text. No direct contradictions were present. Minor ambiguity exists only in whether the claim explicitly includes the label's requirement that Rasuvo be contraindicated during pregnancy, but the interpreted claim context includes this.
Category Scores
Accurate Statements
Methotrexate/Rasuvo can cause embryo-fetal toxicity, including fetal death.
Supported by BOXED WARNING and 5.2 Embryo-Fetal Toxicity / 8.1 Pregnancy in the supplied label text: “Methotrexate can cause embryo-fetal toxicity, including fetal death. Use is contraindicated during pregnancy.”
Severe toxic reactions can occur and may be fatal.
Supported by BOXED WARNING and 5.1 Organ System Toxicity: “Because of the possibility of serious toxic reactions (which can be fatal)…”
Rasuvo is contraindicated during pregnancy.
Supported by 5.2 and 8.1 in the supplied label text: “In pregnant women Rasuvo is contraindicated.”
Unsupported Statements
Contradictions
Important Omissions
The claim does not explicitly mention additional boxed-warning/label elements such as the requirement that Rasuvo “should be used only” by experienced physicians and only for severe, recalcitrant, disabling psoriasis/RA not responding to other therapy.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are directly aligned with boxed-warning and pregnancy/embryo-fetal toxicity content, without introducing unsupported or contradictory safety claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of some boxed-warning context (restricted use criteria beyond pregnancy/embryo-fetal toxicity).
Suggested Improvement
Include the boxed-warning language that Rasuvo “should be used only” by physicians experienced with antimetabolite therapy and reserved for severe, recalcitrant, disabling psoriasis or RA not adequately responsive to other therapy.